Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038454 (
stroke
)
147,016
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cardiac function was investigated in conscious normotensive rats in which increased aortic stiffness was produced as a result of vascular calcium overload after treatment with vitamin D3 plus nicotine (
VDN
rats, n = 16; controls, n = 17). Baseline
stroke
volume, cardiac output, and cardiac response to a venous volume overload were unchanged after 1 mo of exposure to increased aortic stiffness, as were baseline venous return and total vascular capacitance. The latter was estimated from the change in mean circulatory filling pressure after modification of circulatory volume. Cardiovascular reflexes were modified in
VDN
rats. Bradycardia evoked by an increase in arterial PCO2 (PaCO2) or hypotensive hemorrhage was more pronounced. The PaCO2-induced bradycardia was accompanied by a fall in cardiac output in
VDN
rats but not in controls. In
VDN
rats, the attenuation of sympathetic reflexes may explain the slower recovery of blood pressure after hypotensive hemorrhage. In conclusion, a chronic increase in aortic stiffness does not compromise cardiac performance, but cardiovascular reflexes are impaired in
VDN
rats. Whether this is because of the increase in aortic stiffness or the effect of
VDN
treatment on the baroreceptors or other components of the reflex arc remains to be elucidated.
...
PMID:Cardiac function in a rat model of chronic aortic stiffness. 917 88
In elderly patients, aortic stiffness is a major determinant of increased end-systolic stress leading to left ventricular (LV) hypertrophy with impaired cardiac performance. However, in a rat model of aortic elastocalcinosis (induced by vitamin D(3)-nicotine [
VDN
] treatment), brief exposure (1 month) to increased aortic stiffness modified neither cardiac function nor cardiac structure. Here we report the impact of longer exposure (3 months) to aortic stiffness. Three months after induction of aortic stiffness, aortic characteristic impedance was measured in awake rats, 8 control and 10
VDN
.
Stroke
volume was measured (electromagnetic probe) at baseline and after acute volume overload. LV weight/body weight ratio, collagen, and myosin heavy chain (MHC) contents were determined. Although aortic characteristic impedance increased (controls, 32+/-2;
VDN
rats, 50+/-8 10(3) dyne. s/cm(5); P=0.0248),
stroke
volume was maintained in
VDN
rats at baseline (controls, 223+/-18;
VDN
, 211+/-13 microL) and after volume overload (controls, 378+/-14;
VDN
, 338+/-15 microL). However, LV weight/body weight ratio (controls, 1.54+/-0.07;
VDN
, 1.73+/-0.05 g/kg; P=0.0397) and LV collagen content (controls, 31+/-4;
VDN
, 52+/-4 microgram/g dry wt; P=0.0192) increased. A shift from alpha-MHC (controls, 82+/-2%;
VDN
, 69+/-3%; P=0.0056) to beta-MHC (controls, 18+/-2%;
VDN
, 31+/-3%; P=0. 0056) was also observed. Three months' exposure to increased aortic stiffness in
VDN
rats induced LV hypertrophy with moderate interstitial fibrosis and a shift in the MHC-isoform pattern. Such structural adaptation maintains LV performance.
...
PMID:Cardiac consequences of prolonged exposure to an isolated increase in aortic stiffness. 1040 25
The vitamin D(3) and nicotine (
VDN
) model is a model of isolated systolic hypertension (ISH) due to arterial calcification raising arterial stiffness and vascular impedance similar to an aged and stiffened arterial tree. We therefore analyzed the impact of this aging model on normal and diseased hearts with myocardial infarction (MI). Wistar rats were treated with
VDN
(n = 9), subjected to MI by coronary ligation (n = 10), or subjected to a combination of both MI and
VDN
treatment (
VDN
/MI, n = 14). A sham-treated group served as control (Ctrl, n = 10). Transthoracic echocardiography was performed every 2 wk, whereas invasive indexes were obtained at week 8 before death. Calcium, collagen, and protein contents were measured in the heart and the aorta. Systolic blood pressure, pulse pressure, thoracic aortic calcium, and end-systolic elastance as an index of myocardial contractility were highest in the aging model group compared with MI and Ctrl groups (P(
VDN
) < 0.05, 2-way ANOVA). Left ventricular wall stress and brain natriuretic peptide (P(VDNxMI) = not significant) were highest, while ejection fraction,
stroke
volume, and cardiac output were lowest in the combined group versus all other groups (P(VDNxMI) < 0.05). The combination of ISH due to this aging model and MI demonstrates significant alterations in cardiac function. This model mimics several clinical phenomena of cardiovascular aging and may thus serve to further study novel therapies.
...
PMID:Effects of an aging vascular model on healthy and diseased hearts. 1761 50
The PDE-5 inhibitors sildenafil (Viagra) vardenafil (
Levitra
) and tadalafil (Cialis) have been taken by millions of men for erectile dysfunction. Transient visual symptoms are common but there also have been fourteen cases of nonarteritic anterior ischemic optic neuropathy (NAION) described in patients using these drugs as well as a few other vascular events. NAION is a common optic neuropathy in patients in the age group using these drugs and the question arises whether or not PDE-5 inhibitors are causing NAION. One case of NAION occurred after transient visual symptoms occurred with repeated use and one patient experienced a transient ischemic attack after taking a dose followed by a
stroke
on using the drug again later. Other than these two cases with strong dechallenge-rechallenge data, the evidence to support PDE-5 inhibitors as a cause of NAION or any vascular event is weak. PDE-5 inhibitors probably are a rare cause of a common ischemic disorder of the optic disc. They should be avoided in men who have already experienced NAION in one eye. Patients should be warned to seek medical attention if they have visual field or acuity loss after using PDE-5 inhibitors. Otherwise there is little basis for modifying the current guidelines for the use of these drugs.
...
PMID:Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence? 1770 72
Vardenafil
is a potent phosphodiesterase-5 (PDE-5) inhibitor used in the treatment of erectile dysfunction. Several cases of
stroke
related to the use of PDE-5 inhibitors have been reported. Here, we describe the case of a 51-year-old man with headache and right ophthalmoplegia subsequent to vardenafil consumption. Computed tomography and magnetic resonance imaging showed a suprasellar mass with hemorrhage suggesting pituitary
apoplexy
. He underwent transsphenoidal resection of the pituitary mass. Histopathology confirmed the diagnosis of a necrotic pituitary adenoma with hemorrhage. This report suggests a possible association between pituitary
apoplexy
and vardenafil use. In patients with preexisting pituitary adenoma, vardenafil may enhance the risk of pituitary
apoplexy
. Although headache is the most commonly reported side effect of vardenafil, pituitary
apoplexy
should be considered in the differential diagnosis of a patient with headache and ophthalmoplegia subsequent to vardenafil intake.
...
PMID:Pituitary adenoma apoplexy associated with vardenafil intake. 3054 75